What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price… Continue Reading
Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board. In this wide ranging conversation Dr. Stefan… Continue Reading
In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together with negotiating expert and lawyer Bibiane Schulte-Bosse. Get into the hot areas of AMNOG – the negotiations and let us… Continue Reading
In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access. Who else could better speak about the Swiss system with… Continue Reading
In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany. Mathias is a core stakeholder within the regional payer system in… Continue Reading
